![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/19725942-668698754-picture1-jpg-100x28.jpeg)
Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 ...
AGOURA HILLS, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC). Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured …